Mardia Samyoung Q2FY27: standalone PAT ₹0.98 Cr, revenue ₹23.4 Cr, down ~6% QoQ

Mardia Samyoung Capillary Tubes reported standalone revenue of ₹23.38 Cr and PAT of ₹0.98 Cr (NPM 4.19%, EPS ₹0.12) for Q2 FY27 — a sequential (QoQ) dip of 5.9% on revenue and 6.9% on PAT from Q1 FY27's ₹24.84 Cr revenue / ₹1.05 Cr PAT (NPM 4.23%). Year-on-year, both lines are up roughly 56x against Q2 FY26 (₹0.41 Cr revenue, ₹0.02 Cr PAT), but that comparison is not meaningful: the year-ago quarter sat on a near-zero base before the company's trading business scaled up in Q1 FY27, so the headline YoY percentage is a base-effect artifact, not organic growth. The more informative read is sequential: margins held broadly flat around 4.2% NPM and ~5.5% pre-tax (OPM proxy, down from 5.72% in Q1 FY27), consistent with a low-margin agri-trading operation (the company's only reportable segment per Note 4 is 'Trading of Agriculture Product', a notable disconnect from the capillary-tubes name). For H1 FY27, PAT was ₹2.03 Cr against a ₹(0.21) Cr loss in H1 FY26. The company has no analyst/street coverage (a web search for Q2 FY27 previews or consensus estimates returned no analyst estimates for this stock — only prior-quarter actuals), so vsStreet is unknown; management has issued no formal guidance or concall commentary on record, so vsGuidance cannot be assessed either, and there is no press release beyond the standard board-outcome letter. The more notable angle this quarter is working-capital quality rather than the P&L print: trade receivables rose to ₹79.08 Cr as of 30-Sep-26 from ₹55.72 Cr at 31-Mar-26 — a jump roughly matching the half-year's ₹48.22 Cr revenue — while net cash from operating activities for H1 was negative ₹12.01 Cr despite a H1 accounting profit of ₹2.03 Cr. The statutory auditors' Emphasis of Matter again notes that trade receivables, trade payables, loans/advances and borrowings are unconfirmed and unreconciled with counterparties, a recurring caveat on this filing. Paid-up equity capital also rose to ₹79.46 Cr from ₹67.75 Cr at 31-Mar-26 on warrant conversions (per the Q1 FY27 filing, ~₹15.82 Cr raised), which is dilutive to per-share metrics even as absolute profit holds up.